Drug Trial Radar · NCT00359762
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,029
Actual
Start
Sep 2006
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Aug 2, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.
Conditions
- Type 2 Diabetes Mellitus
Interventions
exenatideDrug
subcutaneous injection (5mcg or 10mcg), twice a day
glimepirideDrug
oral tablet (titrated to maximally tolerated dose), once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Treatment FailureTime frame: Baseline to end of Period II (up to 4.5 years)
- Time to Treatment FailureTime frame: Baseline to end of Period II (up to 4.5 years)
Locations
114 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Graz, Austria
Research Site
Innsbruck, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Beroun, Czechia
Research Site
České Budějovice, Czechia
Research Site
Hradec Králové, Czechia
Research Site
Liberec, Czechia
Research Site
Písek, Czechia
Research Site
Prague, Czechia
Research Site
Třebíč, Czechia
Research Site
Helsinki, Finland
Research Site
Kuopio, Finland
Research Site
Pori, Finland
Research Site
Vaasa, Finland
Research Site
Alençon, France
Research Site
Bois-Guillaume, France
Research Site
Bourg-des-Comptes, France
Research Site
Broglie, France
Research Site
Bron, France
Research Site
Fléville-devant-Nancy, France
Research Site
Le Creusot, France
Research Site
Le Mans, France
Research Site
Loudun, France
Research Site
Montigny-lès-Metz, France
Research Site
Nevers, France
Research Site
Strasbourg, France
Research Site
Thouars, France
Research Site
Tours, France
Research Site
Valréas, France
Research Site
Vénissieux, France
Research Site
Vihiers, France
Research Site
Altona, Germany
Research Site
Aschaffenburg, Germany
Research Site
Bad Staffelstein, Germany
Research Site
Dresden, Germany
Research Site
Eisenach, Germany
Research Site
Essen, Germany
Research Site
Essen Schonnebeck, Germany
Research Site
Falkensee, Germany
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.